Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Primary hyperoxaluria 1 (PH1) is a devastating condition involving recurrent urolithiasis, early end-stage renal disease and multisystemic deposition of calcium oxalate crystals. Treatment options for PH1 are limited, inevitably requiring transplantation, usually combined kidney and liver transplant. Here we report successful compassionate use of Nedosiran, an RNA interference targeting lactate dehydrogenase, in an index patient. Monthly Nedosiran injections led to dramatically decreased plasma oxalate levels, decreased frequency of weekly hemodialysis sessions from 6 to 3, and deferral of combined kidney and liver transplant. Nedosiran represents a novel and impactful potential therapeutic for PH1 patients with end-stage renal disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.urology.2021.03.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Global genetic prevalence estimates of primary hyperoxaluria are greater than previously reported.
Clin Kidney J
July 2025
Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Background: Primary hyperoxaluria (PH), a rare autosomal recessive disease of oxalate accumulation in the kidneys, is caused by biallelic pathogenic changes in three known genes: (PH1), (PH2) and (PH3).
Methods: To better understand the overall risk of developing clinical PH, we manually curated and classified PH genetic variants and calculated the estimated genetic prevalence overall and in five ethnic subpopulations using allelic frequencies from the population Genome Aggregation Database (gnomAD version 2.1.
Liver Transplantation in Childhood: A 2-Year Single Center Experience.
Transplant Proc
August 2025
Florya VM Medical Park Application and Research Hospital, Organ Transplantation Center, Dr. Istanbul Aydın University, Istanbul, Turkey.
Objective: Liver transplantation is currently the most treatment for fulminant hepatitis, end-stage liver failure, hepatocellular carcinoma, and liver-originated metabolic diseases in children. With technological advances, improvements in surgical techniques and immunosuppressive therapy protocols have increased 1-year survival rates to 80%-90%. Our center successfully performs both living donor and cadaveric liver transplants in children.
View Article and Find Full Text PDFWhole Exome Sequencing in Chinese Pediatric Patients With Nephrolithiasis.
Kidney Int Rep
August 2025
Department of Urology, Beijing Friendship Hospital, Capital Medical University, China.
Introduction: The incidence of pediatric nephrolithiasis has been increasing, and the role of genetic factors has garnered attention in recent years. This study aimed to explore the genetic basis underlying pediatric nephrolithiasis in Chinese population.
Methods: Whole exome sequencing (WES) was conducted in a consecutive cohort of 456 children over a 11-year period.
The evolving role of liver transplantation as enzyme replacement therapy in the era of RNA nanotherapies.
Am J Transplant
August 2025
Toronto General Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada; Ajmera Transplant Center, University Health Network, University of Toronto, Toronto, Ontario, Canada. Electronic address:
Solid organ transplantation (SOT) is a treatment for monogenic diseases like transthyretin amyloidosis (ATTR) and primary hyperoxaluria (PH). The advent of RNA nanotherapy has introduced new disease-modifying options for ATTR and PH. We examined the prevalence, clinical characteristics, and outcomes of SOT waitlisted candidates (due to ATTR/PH) pre-US Food and Drug Administration (US FDA) and post-US FDA approval of patisiran and lumasiran, respectively.
View Article and Find Full Text PDFGenetic and Clinical Characterization of a Large Cohort with Suspected Monogenic Stone Disease.
Clin J Am Soc Nephrol
August 2025
Division of Nephrology and Hypertension.
Background: Urinary stone disease with a clear genetic cause, monogenic stone disease (MSD), is increasingly recognized as a significant proportion of the total population. When MSD is suspected, genetic testing provides a firm diagnosis that can alter management and treatment. Here we present testing results from a large cohort with suspected MSD.
View Article and Find Full Text PDF